Table 1. Tumor and patient characteristics with NSCLC (grouped by tumor-stroma ratio).
| Characteristics | Total (N=261), n (%) | Stroma poor (N=223), n (%) | Stroma rich (N=38), n (%) | P |
|---|---|---|---|---|
| Gender | 0.462 | |||
| Women | 96 (36.8) | 80 (35.9) | 16 (42.1) | |
| Men | 165 (63.2) | 143 (64.1) | 22 (57.9) | |
| Smoking history (P.Y) | 0.715 | |||
| <20 | 144 (55.2) | 122 (54.7) | 22 (57.9) | |
| ≥20 | 117 (44.8) | 101 (45.3) | 16 (42.1) | |
| Age (year) | 0.763 | |||
| ≤65 | 173 (66.3) | 147 (65.9) | 26 (68.4) | |
| >65 | 88 (33.7) | 76 (34.1) | 12 (31.6) | |
| Differentiation grade | 0.443 | |||
| Well | 27 (10.3) | 24 (10.8) | 3 (7.9) | |
| Moderate | 132 (50.6) | 109 (48.9) | 23 (60.5) | |
| Poor | 102 (39.1) | 90 (40.4) | 12 (31.6) | |
| Histology | 0.181 | |||
| ADC | 182 (69.7) | 152 (68.2) | 30 (78.9) | |
| SCC | 79 (30.3) | 71 (31.8) | 8 (21.1) | |
| pT status | 0.753 | |||
| pT1 | 119 (45.6) | 101 (45.3) | 18 (47.4) | |
| pT2 | 125 (47.9) | 106 (47.5) | 19 (50.0) | |
| pT3/4 | 17 (6.5) | 16 (7.2) | 1 (2.6) | |
| pN status | 0.202 | |||
| pN0 | 178 (68.2) | 151 (67.7) | 27 (71.1) | |
| pN1 | 36 (13.8) | 34 (15.2) | 2 (5.3) | |
| pN2 | 47 (18.0) | 38 (17.0) | 9 (23.7) | |
| Adjuvant therapy | 0.058 | |||
| No | 121 (46.4) | 98 (43.9) | 23 (60.5) | |
| Yes | 140 (53.6) | 125 (56.1) | 15 (39.5) | |
| pTNM stage | 0.188 | |||
| I | 157 (60.2) | 131 (58.7) | 26 (68.4) | |
| II | 57 (21.8) | 53 (23.8) | 4 (10.5) | |
| III | 47 (18.0) | 39 (17.5) | 8 (21.1) |
P<0.05 was considered significant. NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SCC, squamous carcinoma; pT, pathological tumor stage; pN, pathological node stage; pTNM, tumor node metastasis; P.Y, package year.